GleamWall
中文EN

RNAZ Transcode Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1829635 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-435.7%
TTM EPS YoY81.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-866.1%
ROA-581.7%
ROIC (approx.)-909.8%
Asset turnover—

Leverage & solvency

Liabilities / assets28.2%
Debt / equity0.00x
Current ratio0.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-476.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$13.42M$9.71M
SG&A expense$5.77M$5.95M
Operating income-$27.98M-$15.66M
Interest expense$6,616$26,813
Pretax income-$34.44M-$16.75M
Income tax$226,069$0
Net income-$34.66M-$16.75M
EBITDA-$27.90M-$15.57M
EPS (basic)-52.59-1,336.63
EPS (diluted)-52.59-1,336.63
Weighted avg. shares (diluted)689,71312,558
Balance sheet
Cash & equivalents$17.81M$5.81M
Current assets$21.98M$7.09M
PP&E, net$370,681$51,574
Goodwill$25.74M—
Intangibles$114.30M—
Total assets$162.40M$7.29M
Current liabilities$3.49M$2.77M
Total liabilities$10.52M$9.31M
Shareholders' equity$10.34M-$2.02M
Shares outstanding916,96836,753
Cash flow statement
Operating cash flow-$19.52M-$13.34M
Capital expenditure$6,660$21,761
Free cash flow-$19.52M-$13.36M
Investing cash flow-$4,436-$21,761
Financing cash flow$31.52M$16.40M
Depreciation & amortization$76,446$90,894
Stock-based compensation$485,428$1.70M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.